Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Manuel Payán Ortiz"'
Autor:
Marina Blanco-Ruiz, Laura Amaya-Pascasio, Reyes de Torres Chacón, María Josefa Álvarez Soria, Antonio Arjona-Padillo, María Magdalena Carrillo Bailén, Rodrigo Milán Pinilla, Irene Pérez Ortega, Belén Sánchez Rodríguez, Luis Andrade Zumárraga, Roberto Valverde Moyano, Manuel Payán Ortiz, Alba María Castillo Fernández, Cristina Del Toro Pérez, Pablo González Bustos, Eduardo Agüera Morales, Purificación Sánchez López, Beatriz Hidalgo Martín, Ricardo Roa Chamorro, Javier Fernández Pérez, María Victoria Mejías Olmedo, Patricia Martínez-Sánchez
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss , Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Externí odkaz:
https://doaj.org/article/b020ee4ca2c84b4e8348c9ae45697a6f
Autor:
Cristina del Toro Pérez, Laura Amaya Pascasio, Antonio Arjona Padillo, Jesús Olivares Romero, María Victoria Mejías Olmedo, Javier Fernández Pérez, Manuel Payán Ortiz, Patricia Martínez-Sánchez
Publikováno v:
Brain Sciences, Vol 11, Iss 6, p 776 (2021)
Non-motor symptoms (NMS) in Parkinson’s disease (PD), including neuropsychiatric or dysautonomic complaints, fatigue, or pain, are frequent and have a high impact on the patient’s quality of life. They are often poorly recognized and inadequately
Externí odkaz:
https://doaj.org/article/a9e3242e0342435a8ed5fab04eed2250
Autor:
Rodrigo Milán Pinilla, María Magdalena Carrillo Bailén, Marina Blanco-Ruiz, María Josefa Álvarez Soria, Belén Sánchez Rodríguez, Patricia Martínez-Sánchez, Laura Amaya-Pascasio, Roberto Valverde Moyano, Irene Pérez Ortega, María Victoria Mejías Olmedo, Pablo González Bustos, Javier Fernández Pérez, Purificación Sánchez López, Reyes de Torres Chacón, Eduardo Agüera Morales, Manuel Payán Ortiz, Luis Andrade Zumárraga, Antonio Arjona-Padillo, Alba María Castillo Fernández, Cristina Del Toro Pérez, Beatriz Hidalgo Martín, Ricardo Roa Chamorro
Publikováno v:
Atherosclerosis Plus, Vol 45, Iss, Pp 32-38 (2021)
Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine cl
Autor:
Patricia Martínez-Sánchez, Javier Fernández Pérez, Antonio Arjona Padillo, Manuel Payán Ortiz, Laura Amaya Pascasio, María Victoria Mejías Olmedo, Cristina Del Toro Pérez, Jesús Olivares Romero
Publikováno v:
Brain Sciences
riUAL. Repositorio Institucional de la Universidad de Almería
Universidad de Almería
Brain Sciences, Vol 11, Iss 776, p 776 (2021)
riUAL. Repositorio Institucional de la Universidad de Almería
Universidad de Almería
Brain Sciences, Vol 11, Iss 776, p 776 (2021)
Non-motor symptoms (NMS) in Parkinson’s disease (PD), including neuropsychiatric or dysautonomic complaints, fatigue, or pain, are frequent and have a high impact on the patient’s quality of life. They are often poorly recognized and inadequately
Autor:
Rosa Querol-Pascual, José Galván-Espinosa, Pedro J. Serrano-Castro, Antonio Arjona-Padillo, Manuel Payán-Ortiz, José Manuel Molto-Jorda, Mauri-Llerda Ja, Javier Fernández-Pérez, Vicente Bertol-Alegre, Jose Carlos Estevez-Maria, José Francisco Maestre-Moreno, Diego Tortosa-Conesa, Manuel Toledo-Argany, Alberto García-Martínez, Jesús Ruiz-Giménez, Francisco Javier López-González
Publikováno v:
Epilepsy research. 138
Evaluate if eslicarbazepine acetate (ESL) in combination with other non-inducer antiepileptic drugs (AEDs) in the treatment of epilepsy may represent a positive impact in the cardiovascular risk profile.multicentre, retrospective, observational, non-
Autor:
Pedro J, Serrano-Castro, Manuel, Payán-Ortiz, José M, Cimadevilla, Pablo, Quiroga-Subirana, Javier, Fernández-Pérez
Publikováno v:
Revista de neurologia. 56(6)
INTRODUCTION. Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed in Spain in February 2011 as an adjunctive therapy in adults with partial seizures with or without secondary generalization. Clinical trials with ESL have demonstr
Autor:
Enrique Alonso-Morillejo, Carmen Pozo-Muñoz, Pablo Quiroga-Subirana, Pedro J. Serrano-Castro, Manuel Payán-Ortiz, Javier Fernández-Pérez
Publikováno v:
Clinical neurology and neurosurgery. 115(8)
The predominant manifestations of temporal lobe epilepsy (TLE) are partial seizures with impairment of consciousness (type I.B of ILAE classification), although consciousness impairment is not necessary in all seizures of patients with TLE. Neverthel
Autor:
Pedro J. Serrano-Castro, Manuel Payán-Ortiz, Pablo Quiroga-Subirana, Javier Fernández-Pérez, Tesifón Parrón-Carreño
Publikováno v:
Epilepsy research. 101(1-2)
Summary Introduction Temporal Lobe Epilepsy (TLE) is frequently resistant to drug treatment, but a high percentage of these patients can be free of seizures after epilepsy surgery. Delay in the surgical decision has been related to quality of life im
Autor:
Cristina, Naranjo-Fernández, Antonio, Arjona, Pablo, Quiroga-Subirana, Manuel, Payán-Ortiz, Pedro, Guardado-Santervás, Pedro J, Serrano-Castro, Almudena, Aguilera-Del Moral
Publikováno v:
Revista de neurologia. 50(4)
Impaired memory, and more particularly spatial orientation, occurs in pathologies such as dementia, cerebrovascular accidents or traumatic brain injuries. Less frequently it also appears as a transient disorder in healthy people with no apparent brai
Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia
Publikováno v:
Urologia internationalis. 81(1)
Objective: To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH). An evaluation is made of the number of patients recovering spontane